Cargando…

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia

Aim: There is an unmet need in Japan for more optimal lipid-lowering therapy (LLT) for patients with homozygous familial hypercholesterolemia (HoFH) who respond inadequately to available drug therapies and/or apheresis, to achieve goals of low-density lipoprotein cholesterol (LDL-C) reduction by 50%...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harada-Shiba, Mariko, Ikewaki, Katsunori, Nohara, Atsushi, Otsubo, Yoshihiko, Yanagi, Koji, Yoshida, Masayuki, Chang, Qing, Foulds, Pamela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392478/ https://www.ncbi.nlm.nih.gov/pubmed/28154305 http://dx.doi.org/10.5551/jat.38216

Ejemplares similares

Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
por: Nohara, Atsushi, et al.
Publicado: (2019)

Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Kameyama, Noriko, et al.
Publicado: (2019)

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Homozygous Familial Hypercholesterolemia
por: Nohara, Atsushi, et al.
Publicado: (2021)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them
por: Yoshida, Hiroshi
Publicado: (2017)

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
por: Larrey, Dominique, et al.
Publicado: (2022)

Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study
por: D’Erasmo, Laura, et al.
Publicado: (2022)

Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting
por: Mahzari, Moeber, et al.
Publicado: (2021)

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia
por: Blom, Dirk J., et al.
Publicado: (2018)

Guidance for Pediatric Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report
por: Littmann, Karin, et al.
Publicado: (2020)

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
por: Ben-Omran, Tawfeg, et al.
Publicado: (2019)

What Arteries are Affected in Familial Hypercholesterolemia?
por: Harada-Shiba, Mariko
Publicado: (2019)

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Yamashita, Shizuya, et al.
Publicado: (2022)

Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene
por: Tada, Hayato, et al.
Publicado: (2022)

Impact of Familial Hypercholesterolemia Diagnosis in Real-World Data
por: Harada-Shiba, Mariko
Publicado: (2023)

Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome: Genetic Insights from EXPLORE-J
por: Harada-Shiba, Mariko, et al.
Publicado: (2022)

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

The Roles of Genetic Analysis in the Diagnosis of Pediatric Patients with Familial Hypercholesterolemia
por: Harada-Shiba, Mariko
Publicado: (2022)

Homozygous familial hypercholesterolemia
por: Parihar, Ravi Kumar, et al.
Publicado: (2012)

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Ogura, Masatsune, et al.
Publicado: (2022)

Xanthoma tuberosum in homozygous familial hypercholesterolemia
por: Moorthy, Nagaraja, et al.
Publicado: (2014)

Liver Transplantation for Homozygous Familial Hypercholesterolemia
por: Ishigaki, Yasushi, et al.
Publicado: (2019)

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab
por: Jeraj, Natasha, et al.
Publicado: (2021)

Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
por: Bajaj, Archna, et al.
Publicado: (2022)

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Naito, Ryo, et al.
Publicado: (2022)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J
por: Nakamura, Masato, et al.
Publicado: (2021)

Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society
por: Funabashi, Sayaka, et al.
Publicado: (2021)

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
por: Kataoka, Yu, et al.
Publicado: (2022)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2015)

Homozygous familial hypercholesterolemia with an update on cholesterol management
por: Velvet, Anju J J, et al.
Publicado: (2020)

New algorithms for treating homozygous familial hypercholesterolemia
por: Tromp, Tycho R., et al.
Publicado: (2022)

Current Treatment Options in Homozygous Familial Hypercholesterolemia
por: Kayikcioglu, Meral, et al.
Publicado: (2022)

A reassessment of the Japanese clinical diagnostic criteria of familial hypercholesterolemia in a hospital-based cohort using comprehensive genetic analysis
por: Tada, Hayato, et al.
Publicado: (2020)

A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting
por: Blom, Dirk J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4u9p0vbln6mdjhg56hgjar73f0